Study	Reason for exclusion
Fariba 2016	A prospective randomised clinical trial comparing intravenous (IV) MTX and IV Act‐D in the treatment of low‐risk gestational trophoblastic neoplasia, invasive mole, and choriocarcinoma.
Geng 2011	A retrospective study evaluating characteristics and outcomes for 23 women with high‐risk HM who received prophylactic chemotherapy (5‐FU or dactinomycin).
Mousavi 2012	A RCT of 75 patients with low‐risk GTD (FIGO stage I, II, or III disease, a WHO risk score of 6 or less), 50 receiving pulsed actinomycin D and 25 receiving 5‐day methotrexate.
Uberti 2006	A retrospective study evaluating a bolus dose of dactinomycin for prevention of persistent GTD in 29 adolescents with high‐risk molar pregnancy compared with a similar control group of 31 adolescents.
Uberti 2009	A retrospective study evaluating the effect of a bolus dose of dactinomycin, given 1 hour before ERPC to women with high‐risk HM, on the rate of malignant transformation to GTN.

5‐FU: 5‐fluorouracil; ERPC: evacuation of retained products of conception; GTD: gestational trophoblastic disease; GTN: gestational trophoblastic neoplasia; HM: hydatidiform mole.